Home Page
Richard S. Schwartz, M.D.
Biopharmaceutical Clinical Research Consultant
Pharmaceutical and Biotechnology Development
Burlingame, California USA
Tel: (650) 344-6260
e-mail: rss@netwiz.net
Biopharmaceutical Clinical Research Consultant
Pharmaceutical and Biotechnology Development
Burlingame, California USA
Tel: (650) 344-6260
e-mail: rss@netwiz.net
l. Eastman PM, Schwartz R, Schrier SL: Differences in hemoglobin synthesis in idiopathic ineffective erythropoiesis and diGuglielmo's disease. Clin Res l9:4l7, l97l.
2. Callen J, Schwartz R, Silva J: Epidemiology of Hodgkin's disease: A report of a cluster. Presented at the American Federation of Clinical Research, New Orleans, Louisiana, January l976. Clin Res 24:7A, l976.3. Plouffe J, Callen J, Schwartz R, et al: Lymphocyte hyperreactivity in a town with a cluster of Hodgkin's disease. Presented at national meeting, American Federation of Clinical Research, Atlantic City, New Jersey, l976. Clin Res 24:249A, l976.
4. Schwartz R, Greenberg P, Chen S: Regulation of granulopoiesis by serum lipoprotein inhibitors. Blood 50 (Suppl l): l59, l977. 5. Schwartz R, Richardson S, Greenberg P: Human endosteal bone production of colony stimulating activity (CSA). Blood 52 (Suppl l): 23l, l978. 6. Schwartz RS, Greenberg PL: Infectious complications occurring during AML induction therapy. Blood 54:Suppl l:l60a, l979. Presented at 22nd Annual Meeting, American Society of Hematology, Phoenix, Arizona. December l-4, l979. 7. Schwartz R, Halpern J, Greenberg P: Multivariate analysis of factors predicting outcome of treatment for adults with acute myelogenous leukemia (AML). Presented at the l6th Annual Meeting, American Society of Clinical Oncology, San Diego, California, May 26-27, l980. ASCO Proc 2l:C460, l980. 8. Hill HR, Boline JA, Hogan N, Rote NS, Schwartz RS: Fibronectin deficiency: A correctable defect in the neonate's host defense mechanism. Presented at the Western Meeting, American Federation for Clinical Research, Carmel, California, l983. Clin Res 3l:ll8A, l983. 9. Schwartz R, Ewing N, Boylen AL, Kasper C, Gorenc T. Spero J, Lewis J: Comparative efficacy of treatment with non-heated (NHT) and heat-treated (HT) Konyne in hemophiliacs with inhibitors. Presented at the American Society of Hematology, San Francisco, California, December 6-9, 1986. Blood 68 (Suppl 1): 302a, 1986.10. Kurtzberg J, Friedman HS, Falletta JM, Kinney TR, Chaffee S, Schwartz, RS, Kurlander R: The efficacy of IGIV in autoimmune mediated pediatric blood dyscrasias. Blood 68 (Suppl 1): 112a, 1986.
11. Schwartz R, Kavanagh E, Bauer K, Rosenberg R, et al: Antithrombin III concentrate (AT-III) for prophylaxis and treatment of congenital and acquired AT-III deficiency. Presented at the XIth International Congress on Thrombosis and Haemostasis, Brussels, Belgium, July 1987. Thrombosis Haemostasis 58: 238, 1987.
12. Schwartz RS: Status of Clinical Trials of Human FVIII derived from recombinant DNA. Presented at the NIH-NHLBI Workshop FVIII concentrates: Current Issues and Future Prospects, March 9-10, 1989, Bethesda, MD.
13. Schwartz RS, Abildgaard C. Aledort L, Bloom A, Brackmann H, Brettler D, Dietrich S, Egli J, Fujimaki M, Fukui H, Hilgartner M, Inwood M, Kasper C, Kernoff P, Levine P, Lusher J, Mannucci P, Scharrer I. Status of Clinical Investigation of Human FVIII derived from Recombinant DNA (rFVIII). Presented at National Hemophilia Foundation Annual Meeting, Oakbrook, Il. Oct 12, 1989 (Poster Session).14. Schwartz RS, Abildgaard C. Aledort L, Bloom A, Brackmann H, Brettler D, Dietrich S, Egli J, Fujimaki M, Fukui H, Hilgartner M, Inwood M, Kasper C, Kernoff P, Levine P, Lusher J, Mannucci P, Scharrer I, Allred R, Cox C, Fallise J, Kuo H, MacKenzie S, Maruhn D, Neumann R, Pancham R, Pennington J. Preliminary report of phase I and II clinical investigation of human FVIII derived from recombinant DNA. Presented at the XIIth International Congress on Thrombosis and Haemostasis, Tokyo, Japan, August, 1989. Thrombosis Haemostasis 62: p 181 (#548), 1989.
15. Schwartz RS, Abildgaard C, Aledort L, Arkin S, Bloom A, Brackmann H, Brettler D, Dietrich S, Egli J, Hilgartner M, Inwood M, Kasper C, Kernoff P, Levine P, Lusher J, Mannucci P, Rose E, Scharrer I. Safety and efficacy of recombinant DNA derived FVIII. Presented at the 31st Annual meeting of the American Society of Hematology, Mini-Plenary session, Atlanta, Georgia, December 2, 1989. Blood 74 (Suppl 1): 49a (#175), 1989. 16. Schwartz RS: Recombinant derived blood clotting factors, inclding factor VIII and their potential. Presented at Symposium "Applications of biotechnology in therapeutics and preventive medicine" Royal Society of Medicine, London, United Kingdom, December 6, 1989. 17. Schwartz RS: Clinical trials of factor VIII produced by recombinant technology. Presented at the 21st Annual Scientific Symposium, American Red Cross, May 16, 1990, Washington, DC. 18. Kasper CK, Inwood M, Scharrer I, Bloom A, Schwartz RS: Safety of recombinant factor VIII in home infusion. Presented at the 33rd Annual meeting of the American Society of Hematology, Denver, Colorado, December, 7, 1991. Blood 78 (Suppl 1): 56a (#213), 1991. 19. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM: Clinical experience with high dose intravenous gammaglobulin (IGIV) (Gamimune®-N) in treatment of acquired FVIII inhibitors. Presented at the World Federation of Hemophilia, Athens, Greece, October, 1992. 20. Lusher JM, Arkin S, Abildgaard CF, Mannucci PM, Schwarts RS, and the Kogenate Study Group: rFVIII (Kogenate) in previously untreated subjects with hemophilia A - a three year study. Presented at the International Congress of the World Federation of Hemophilia, Athens, Greece, October, 1992. 21. Abildgaard CF, Inwood MJ, Zimmermann R, Lusher JM, Rousell RH, Schwartz RS: Immune tolerance induction with Kogenate recombinant Factor VIIII in previously untreated patients with high titer inhibitors. Presented at the International Congress of the World Federation of Hemophilia, Athens, Greece, October, 1992. 22. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM: Clinical experience and treatment of acquired factor VIII inhibitors with high dose intravenous gammaglobulin (IGIV) (Gamimune N). Presented at the International Congress of the World Federation of Hemophilia, Athens, Greece, October, 1992. 23. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM: A prospective study of treatment of acquired Factor VIII inhibitors with high dose intravenous gammaglobulin. Presented at the 34th Annual meeting of the American Society of Hematology, Anaheim, CA, December, 1992. Blood 80 (Suppl 1): 230a (# 912), 1992. 24. Mannucci PM, Abildgaard CF, Aledort LM, Lusher JM, Brettler DB, Bogdanoff DA, Schwartz RS and the Kogenate Study Group. Immunologic studies in HIV positive and HIV negative hemophiliacs receiving recombinant factor VIII (Kogenate®) - a 3 year update. Presented at the 34th Annual meeting of the American Society of Hematology, Anaheim, CA, December, 1992. Blood 80 (Suppl 1): 230a (# 909), 1992. 25. Lusher JM, Schwartz RS: Incidence of inhibitor development in infants and children with hemophilia A. Presented at the 34th Annual meeting of the American Society of Hematology, Anaheim, CA, December, 1992. Blood 80 (Suppl 1): 231a (# 914), 1992. 26. Mannucci PM, Abildgaard CF, Aledort LM, Lusher JM, Brettler DB, Bogdanoff DA, Schwartz RS, Hurst D and the Kogenate Study Group: Immune Function over 3.5 years in HIV Positive and HIV Negative Hemophilia Patients receiving Recombinant FVIII (Kogenate®). Presented at 13th Congress of the International Society on Thrombosis and Haemostasis, July, 1993. 27. Mannucci PM, Chediak J, Hanna W, Byrnes JJ, Kessler CM, Ledford M, Retzios AD, Kapelan BA, Gallagher P, Schwartz RS. Treatment of von Willebrand's Disease (vWD) with a high purity factor VIII concentrate: Dissociation between correction of the bleeding time (BT), vWF multimer pattern, and treatment efficacy. Blood 94 (Suppl 1, Part 2): 98b (#3601). 1999. 28. John M. Bennett, Andrew D. Zelenetz, Oliver W. Press, Julie M. Vose, John A. Radford, Susan J. Knox, Mary Wilkinson, Richard S. Schwartz, Mark S. Kaminski, Robert Capizzi.. Incidence of Myelodysplastic Syndromes (tMDS) and Acute Myeloid Leukemia (tAML) in Patients with Low-Grade Non-Hodgkin's Lymphoma (LG-NHL) Treated with Bexxar™. John M. Bennett, Andrew D. Zelenetz, Oliver W. Press, Julie M. Vose, John A. Radford, Susan J. Knox, Mary Wilkinson, Richard S. Schwartz, Mark S. Kaminski, Robert Capizzi. Blood (Suppl 1, Part 2): 335a (#1416), 2001. Presented at the American Society of Hematology Annual Meeting, Orlando, FL, December, 2001. 29. Kuhn JG, Burris HA 3rd, Jones SF, Hein DW, Willcutt NT, Greco FA, Thompson DS, Meluch AA, Schwartz RS, Brown DM.. Phase I/II dose-escalation trial of amonafide for treatment of advanced solid tumors: genotyping to optimize dose based on polymorphic metabolism. J Clin Oncol 25 [18S]: 2503, 2007. .Oral presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June, 2007 30. H. Jean Khoury, Mauricette Michallet, Selim Corm, Lydia Roy, Dan Jones, Andreas Hochhaus, Hagop Kantarjian, Annie-Claude Benichou, Richard Schwartz, and Jorge Cortes. Safety and Efficacy Study of Subcutaneous Homoharringtonine (SC HHT) in Imatinib (IM)-Resistant Chronic Myeloid Leukemia (CML) with the T315I Mutation Initial Report of a Phase II Trial . Presented at the. American Society of Hematology, Annual Meeting, Atlanta, Georgia, December 8, 2007. Blood 110, issue 11, November 16, 2007 Abstract #1050. 31. Le M., Schwartz R, Alsina M, Trudel S, Goy A, Kunkel L Incidence and severity of peripheral neuropathy in heavily pre-treated patients with hematologic malignancies receiving the selective proteasome inhibitor, carfilzomib (PR-171), in a Phase I study. Presented at the Chemotherapy Foundation Symposium XXVI, November 4 – 8, 2008, New York, NY. 32. Sundar Jagannath, Ravi Vij, A. Keith Stewart, George Somlo, Andrzej Jakubowiak, Tony Reiman, Suzanne Trudel, Jessica Taylor, Diana Fuhrman, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David Siegel, and The Multiple Myeloma Research Consortium (MMRC). Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM). Presented at the American Society of Hematology Annual Meeting, San Francisco, CA, December 9, 2008 Abstract #5718 (oral presentation).33. Ravi Vij, Michael Wang, Robert Orlowski, A. Keith Stewart, Sundar Jagannath, Vishal Kukreti, Jessica Taylor, Diana Fuhrman, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David Siegel, and The Multiple Myeloma Research Consortium (MMRC). Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM). Presented at the American Society of Hematology Annual Meeting, San Francisco, CA, December 9, 2008 Abstract #6116 (oral presentation).
34. Sundar Jagannath, Ravi Vij, A. Keith Stewart, George Somlo, Andrzej Jakubowiak, Tony Reiman, Suzanne Trudel, Jessica Taylor, Diana Fuhrman, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David Siegel, and The Multiple Myeloma Research Consortium (MMRC). Carfilzomib in Relapsed and Refracdtory Myeloma. Presented at the 12th International Myeloma Workshop (IMW), Washington, DC, February 27, 2009 (oral presentation).
35. Ravi Vij, Michael Wang, Robert Orlowski, A. Keith Stewart, Sundar Jagannath, Vishal Kukreti, Jessica Taylor, Diana Fuhrman, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David Siegel, and The Multiple Myeloma Research Consortium (MMRC). Phase II Study of Carfilzomib in Relapsed Myeloma. Presented at the 12th International Myeloma Workshop (IMW), Washington, DC, February 27, 2009 (oral presentation).
36. S. Jagannath, R. Vij, K. Stewart, G. Somlo, A. Jakubowiak, S. Trudel, R. Schwartz, D. Siegel, L. Kunkel, The Multiple Myeloma Research Consortium (MMRC). Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol 27:15s, 2009 (suppl; abstr 8504). Presented at the American Society of Clinical Oncology Annual Meeting, Orlando, FL, June 1, 2009 (oral presentation).
37. KC Shih, JA. Bacha, D Brown, W Garner, A Steino, R Schwartz, HA. Burris III. Phase I/II Study of VAL-083 in Patients with Malignant Glioma. Presented at Society of Neurooncology, November, 2012, Washington, DC (poster).
38. KC Shih, JA Bacha, D Brown, WJ Garner, R Schwartz, HA. Burris, III. Phase I/II study of VAL-083 in patients with recurrent malignant glioma or secondary brain tumor. Presented at the American Association for Cancer Research annual meeting, April 10, 2013, Washington, DC (poster).
39. KC Shih, JA Bacha, D Brown, WJ Garner, A Steino, R Schwartz, S Kanekal, M Li, L Lopez, HA Burris III. Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioma or Progressive-Secondary Brain Tumor. Presented at Society of Neuro-oncology, November 22, 2013, San Francisco, CA (poster).
40. KC Shih, MR Patel, J Bacha, DM Brown, WJ Garner, A Steino, RS Schwartz, S Kanekal, M Li, LM Lopez, HA Burris, III. Phase I/II study of VAL-083 in patients with recurrent glioblastoma multiforme. Presented at the American Association for Cancer Research annual meeting, April 9, 2014, San Diego, CA (poster).
41. Shih KC, Patel MR, Butowski NA, Bacha JA, Brown D, Garner WJ, Steino A, Schwartz RS, Kanekal S, Lopez L, Burris HA. Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioblastoma multiforme (GBM). Presented at the American Society of Clinical Oncology annual meeting, May 30, 2014, Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2109) (poster).
42. Shih KC, Patel MR, Butowski NA, Bacha JA, Brown D, Steino A, Schwartz R, Kanekal S, Lopez LM, Burris HA. Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma. Presented at Society of Neuro-oncology, November 14, 2014, Miami Beach, FL (poster).
43. Shih KC, Patel MR, Butowski NA, Bacha JA, Brown D, Steino A, Schwartz RSS, Kanekal S, Lopez L, Jones SF, Burris HA. Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma. Presented at the American Association of Cancer Research, April 20, 2015, Philadelphia, PA. (abstract CT217) (poster).
44. Shih KC, Patel MR, Butowski NA, Bacha JA, Brown D, Steino A, Schwartz RSS, Kanekal S, Lopez L, Jones SF, Burris HA. Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma. Presented at the American Society of Clinical Oncology annual meeting, May 29, 2015, Chicago, IL. J Clin Oncol 33, 2015 (suppl; abstr 2023) (poster).
45. Shih KC, Patel M, Butowski N, et al. Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma. II International Symposium on Clinical and Basic Investigation in Glioblastoma (GBM) 2015, Toledo, Spain, Sep 9-12, 2015 (poster).
46. Shih KC, Patel MR, Butowski N, Bacha JA, Brown DM, Steino A, Schwartz R, Kanekal S, Lopez LM, Burris HA, III. Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma. Presented at Society of Neuro-oncology, November 20, 2015, San Antonio, TX (poster).
47. Shih KC, Patel MR, Butowski N, Falchook G, Kizilbash SH, Bacha JA, Brown DM, Steino A, Schwartz R, Kanekal S, Lopez LM, Burris HA III. Phase I/II study of Dianhydrogalactitol (VAL-083) in patients with recurrent glioblastoma. Presented at the American Association of Cancer Research, April 19, 2016, New Orleans, LO. (abstract CT074) (poster).
48. Shih KC, Patel MR, Butowski N, Falchook G, Kizilbash SH, Bacha JA, Brown DM, Steino A, Schwartz R, Kanekal S, Lopez LM, Burris HA III. Phase I/II study of Dianhydrogalactitol (VAL-083) in patients with recurrent glioblastoma. Presented at the American Society of Clinical Oncology annual meeting, June 5, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 2063) (poster).
49. O'Brien BJ et al. Phase II study of dianhydrogalactitol in patients with MGMT-unmethylated bevacizumab-naïve recurrent glioblastoma. Canadian Neuro-Oncology (CNO) Biennial Meeting 2016, abstract 155 (poster).
50. Bacha JA, et al. Clinical trials of VAL-083 in patients with chemoresistant glioblastoma. Society for Neuro-Oncology (SNO) Annual Meeting Nov, 2016, abstract ACTR-42 (poster).
51. O'Brien BJ, et al. Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma. AACR Annual Meeting 2017, abstract CT054 (poster).
52. Bacha JA, et al. Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma. ASCO Annual Meeting June, 2017, abstract TPS2082 (poster).
53. Bacha JA, et al. Clinical Trials of VAL-083 in Patients with Chemo-Resistant Glioblastoma. WFNOS Annual Meeting 2017, abstract 09.57 (poster).
54. Bacha JA, et al. Clinical trials with Dianhydrogalactitol (VAL-083) in MGMT-unmethylated glioblastoma. Society for Neuro-Oncology (SNO) Annual Meeting, Nov, 2017, Abstract #5235 (poster).
55. O'Brien B, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naïve recurrent glioblastoma, MGMT-unmethylated. AACR Annual Meeting 2018, abstract CT167 (poster).
56. Chen Z, et al. Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed glioblastoma, MGMT-unmethylated. AACR Annual Meeting 2018, abstract CT168 (poster).
57. Bacha JA, et al. Phase 2 studies of dianhydrogalactitol (VAL-083) in patients with glioblastoma, MGMT-unmethylated. Canadian Neuro-Oncology meeting, May, 2018 (poster).
58. Shih K, et al. Dianhydrogalactitol in Bevacizumab-refractory GBM: Further Analysis of a Phase 1-2 Trial. ASCO Annual Meeting, Chicago, IL, June 2, 2018, Abstract 2061 (poster).
59. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naïve recurrent glioblastoma, MGMT-unmethylated. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naïve recurrent glioblastoma, MGMT-unmethylated. AACR Annual Meeting, April 18, 2018, Chicago, IL, Abstract CT167 (poster).
60. Chen ZP, et al. An open-label, biomarker driven, Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed MGMT-unmethylated GBM. AACR Annual Meeting, April 18, 2018, Chicago, IL, Abstract # CT168 (poster).
61. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-nai¨ve recurrent glioblastoma. Society of NeuroOncology (SNO) Annual Meeting, Nov 20, 2018, Phoenix, AZ, Abstract #ACTR-27 (poster).
62. Chen ZP, et al. Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma. Society of NeuroOncology (SNO) Annual Meeting, Nov 20, 2018, Phoenix, AZ, Abstract ACTR-71 (poster).
63. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting. AACR Annual Meeting, April 1, 2019, Atlanta, GA, Abstract #CT115 (poster).
64. Chen ZP, et al. Phase 2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma. AACR Annual Meeting, April 1, 2019, Atlanta, GA, Abstract CT116 (poster).
65. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Society of NeuroOncology (SNO) Annual Meeting Nov 22, 2019, Phoenix, AZ, Abstract ACTR-12 (poster).
66. Chen ZP, et al. Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM: Half-Way Report. Society of NeuroOncology (SNO) Annual Meeting Nov 22, 2019, Phoenix, AZ, Abstract ACTR-06 (poster).
67. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting. AACR Virtual Annual Meeting II, July 22, 2020, Abstract CT272 (poster).
68. Chen ZP, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly diagnosed, MGMT-unmethylated glioblastoma. AACR Virtual Annual Meeting II, July 22, 2020, Abstract 10227 (poster).
69. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Society of NeuroOncology (SNO) Virtual Annual Meeting, Nov 19, 2020, Abstract CTNI-72 (poster).
70. Chen ZP, et al. Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM. Society of NeuroOncology (SNO) Virtual Annual Meeting, Nov 19, 2020, Abstract CTNI-76 (poster).
71. Chen ZP, et al. Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM. AACR Virtual Annual Meeting, April 10, 2021. Abstract CT172 (poster).
72. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting. AACR Virtual Annual Meeting, April 10, 2021. Abstract CT238 (poster).
73. Chen ZP, et al. Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM. Society for Neuro-Oncology Annual Meeting, Nov 18, 2021. Abstract CTNI-21.
74. O'Brien BJ, et al. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmethylated, bevacizumab naïve glioblastoma in the adjuvant or recurrent setting. Society for Neuro-Oncology Annual Meeting, Nov 18, 2021. Abstract CTNI-26.
75. Guo C, et al. Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM. Society for Neuro-Oncology Annual Meeting, Nov 18, 2022. Abstract 32.
Articles:
l. Eastman PM, Schwartz R, Schrier SL: Distinctions between idiopathic ineffective erythropoiesis and diGuglielmo's disease: clinical and biochemical differences. Blood 40:487-99, l972. 2. Schwartz RS, Callen J, Silva J: Epidemiology of a Hodgkin's disease cluster in a small Michigan community: evidence for environmental factors. American Journal of Epidemiology l08:l9-26, l978. 3. Plouffe J, Silva J, Schwartz R, et al: Abnormal lymphocyte responses in residents of a town with a cluster of Hodgkin's disease. Clinical and Experimental Immunology 35:l63-70, l979. 4. Schwartz RS, Cohen J, Schrier S: Therapy of primary amyloidosis with Melphalan and Prednisone. Archives Internal Medicine l39:ll44-47, l979. 5. Schwartz RS, Greenberg P: The stromal microenvironment of hemopoietic and non-hemopoietic bone in man. Blood 57:77l-80, l98l. 6. Schwartz RS, MacKintosh FR, Schrier SL, Greenberg PL: Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 53:411-19, 1984. 7. Schwartz RS, MacKintosh FR, Halpern J, Schrier SL, Greenberg PL: Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia. Cancer 54:1672-81, 1984. 8. Hill RH, Shigeoka AO, Augustine NH, Pritchard D. Lundblad JL, Schwartz RS: Fibronectin enhances the opsonic and protective activity of monoclonal and polyclonal antibody against Group B streptococci. J Exp Med 159:1618-28, 1984. 9. Schwartz RS, MacKintosh FR, Greenberg PL: Correlative patterns of leukocyte counts at presentation and relapse in acute myelogenous leukemia. Acta Haematologica 75:79-82, 1986. 10. Kurtzberg J, Friedman HS, Chaffee S, Falletta JM, Kinney TR, Schwartz RS, Matthews TJ, Kurlander R: The efficacy of intravenous gammaglobulin in autoimmune mediated pediatric blood dyscrasias. Am J Med 83 (4A): 4-9, 1987. 11. Schwartz RS: Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25. Am J Med 83 (4A): 46-51, 1987. 12. Schwartz RS: Intravenous gammaglobulin in clinical use. The Bulletin of burn Injuries 4: 20-24, 1987. 13. Schwartz RS: The biochemistry and safety of native intravenous gamma globulin (IGIV, pH 4.25). J Clinical Apheresis 4: 89-92, 1988. 14. Schwartz RS, Ewing NP, Gorenc TJ, Spero JA: Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors. Am J Hematology 30: 22-26, 1989. 15. Rousell RH, Kasper CK, Schwartz RS: The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma. Transfusion 29: 208-212, 1989. 16. Schwartz RS, Bauer KA, Rosenberg RD, Kavanagh EJ, Davies DC, Bogdanoff DA, and the Antithrombin III study group. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 87(3B): 53S-60S, 1989. 17. Schwartz R: Appropriate Uses of Intravenous IgG. Proceedings of the 13th Annual Cancer Symposium, Scripps Memorial Hospitals. pp 259-275, Nov, 1989. 18. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner D, Meyers JD, Counts GW, Bowden RA, Petersen FB, Witherspoon RP, Budinger MD, Schwartz RS, Appelbaum FR, Hansen JA, Sanders JE, Thomas ED, Storb R: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323: 705-12, 1990. 19. Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, Kasper CK, Kernoff PBA, Levine PH, Lusher JM, Mannucci PM, Scharrer I, MacKenzie MA, Pancham N, Kuo HS, Allred RU, and the Recombinant Factor VIII Study Group: Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of hemophilia A. New England J Med 323: 1800-5, 1990. 20. Schwartz RS: Clinical trials of factor VIII produced by recombinant technology. In: Hoyer LW, Drohan WN, eds. Recombinant Technology in Hemostasis and Thrombosis. New York, Plenum Press, 1991, 229-233. 21. Pennington JE, Schwartz RS: Design of clinical studies with recombinant factor VIII. Seminars in Hematology 28 (Suppl 1): 27-28, 1991. 22. Schwartz RS, Rousell RH: A summary of the world-wide clinical investigations of recombinant factor VIII. Seminars in Hematology 28 (Suppl 1): 53-54, 1991. 23. Schwartz RS: Recombinant FVIII in hemophilia. New Engl J Med (Letter) 324: 1516, 1991. 24. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The NICHD Intravenous Immunoglobulin Study Group. New Engl J Med 325: 73-80, 1991. 25. Hoffman DL, Quart KA, Schwartz RS: Purification and large scale preparation of antithrombin III and clinical experience in treatment of congenital and acquired deficiency of antithrombin. Miles Science Journal 13: 33-39, 1991. 26. Schwartz RS: Recombinant derived blood clotting factors including factor VIII and their potential. Sangre 36 (Suppl 3): 55-56, 1991. 27. Schwartz R, Boedeker B, Schroeder D, Horlein D: Recombinant derived blood clotting Factor VIII (Kogenate®). Miles Science Journal 14: 19-26, 1992. 28. Lusher JM, Arkin S, Abildgaard C, Schwartz RS and the Kogenant previously untreated patient study group: Recombinant FVIII for the treatment of previously untreated patients with hemophilia A - safety, efficacy, and development of inhibitors. New England Journal of Medicine 328: 453-459, 1993. 29. Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D and the Kogenate Study Group: Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. Blood 83: 1958-1962, 1994. 30. Schwartz RS: Clinical studies utilizing antithrombin III in patients with congenital antithrombin III deficiency. Seminars in Hematology 31 (Suppl 1): 42-51, 1994. 31. Schwartz RS: Clinical studies utilizing antithrombin III in patients with acquired antithrombin III deficiency. Seminars in Hematology 31 (Suppl 1): 52-59, 1994. 32. Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group. Blood. 1994 Apr 1;83(7):1958-62. 33. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM: A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous gammaglobulin. Blood 86: 797-804, 1995. 34. Mannucci, PM, Chediak J, Hanna W, Byrnes J, Ledford M, Kapelan BA, Schwartz RS, Kessler C, and the Alphanate® Study Group. Treatment of von Willebrand Disease with a High Purity Factor VIII/von Willebrand Concentrate. Blood 99: 450-456, Jan 15, 2002. 35. Lusher J, Abildgaard C, Arkin S, Mannucci PM, Zimmermann R, Schwartz L, Hurst D. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost. 2004 Apr;2(4):574-83. 36. Guo C, Yang Q, Li J, Wu S, Deng M, Du X, et al. Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report. Glioma 2019;2:167-73.| Curriculum Vitae | Clinical Research Experience | FDA Approvals | Consulting Projects | Publications | Home Page |
Copyright © 1998 - 2024,